Medicare Enrolled
Dr. Anton Melnyk, MD,FACP
Medical Oncology · Abilene, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Melnyk from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Melnyk? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Melnyk
Dr. Anton Melnyk is a medical oncology in Abilene, TX, with 19 years in practice. Based on federal Medicare data, Dr. Melnyk performed 193,993 Medicare services across 6,588 unique beneficiaries.
Between the years covered by Open Payments, Dr. Melnyk received a total of $18,117 from 39 pharmaceutical and/or device companies across 92 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Melnyk is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in TX$ $18,117 industry payments
Medicare Practice Summary
Medicare Utilization ↗193,993
Medicare services
Top 3% in TX for medical oncology
6,588
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,210 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 89,250 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 17,700 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 16,800 | $0 | $33 |
| Darbepoetin injection (Aranesp) for anemia | 14,847 | $2 | $20 |
| Contrast dye for imaging (iodine-based) | 14,200 | $0 | $3 |
| Iron sucrose injection (Venofer) | 10,100 | $0 | $2 |
| Paclitaxel chemotherapy injection | 7,958 | $0 | $8 |
| Dexamethasone injection (steroid) | 2,776 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,570 | $0 | $24 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,560 | $22 | $181 |
| Immune globulin infusion (Octagam) | 1,490 | $31 | $233 |
| Blood draw (venipuncture) | 1,414 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,283 | $8 | $36 |
| Office visit, established patient (20-29 min) | 1,152 | $61 | $250 |
| Comprehensive metabolic blood panel | 1,114 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 699 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 567 | $97 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 457 | $21 | $157 |
| Carcinoembryonic antigen (cea) protein level | 428 | $19 | $99 |
| Injection, leucovorin calcium, per 50 mg | 411 | $3 | $25 |
| Office visit, established patient (30-39 min) | 407 | $91 | $368 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 324 | $20 | $128 |
| Injection, carboplatin, 50 mg | 324 | $2 | $300 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 312 | $86 | $1,348 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 282 | $47 | $313 |
| Anti-nausea injection (Aloxi/palonosetron) | 230 | $1 | $114 |
| Albumin (protein) level | 223 | $5 | $28 |
| Bilirubin level, total | 223 | $5 | $23 |
| Calcium level, total | 223 | $5 | $30 |
| Carbon dioxide (bicarbonate) level | 223 | $5 | $24 |
| Blood chloride level | 223 | $5 | $25 |
| Blood creatinine level | 223 | $5 | $31 |
| Phosphatase (enzyme) level, alkaline | 223 | $5 | $27 |
| Blood potassium level | 223 | $5 | $30 |
| Liver enzyme (sgot), level | 223 | $5 | $33 |
| Liver enzyme (sgpt), level | 223 | $5 | $28 |
| Urea nitrogen level to assess kidney function, quantitative | 223 | $4 | $24 |
| Total protein level, blood | 220 | $4 | $42 |
| Administration of chemotherapy into vein, each additional hour | 213 | $21 | $161 |
| Lactate dehydrogenase (enzyme) level | 195 | $6 | $31 |
| Hospital follow-up visit, moderate complexity | 170 | $59 | $247 |
| Drug injection, under skin or into muscle | 159 | $10 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 149 | $48 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 149 | $1 | $7 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 149 | $134 | $3,675 |
| Injection of additional new drug or substance into vein | 144 | $12 | $108 |
| Microscopic examination for white blood cells with manual cell count | 129 | $4 | $22 |
| Complete blood count (CBC), automated | 129 | $6 | $34 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 119 | $346 | $1,722 |
| PSA test (prostate cancer screening) | 112 | $18 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 111 | $25 | $145 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 108 | $52 | $211 |
| Ct scan of chest with contrast | 104 | $58 | $821 |
| Magnesium level test | 103 | $7 | $29 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 100 | $69 | $70 |
| Injection, zoledronic acid, 1 mg | 99 | $6 | $431 |
| CT scan of abdomen and pelvis with contrast | 88 | $163 | $1,067 |
| Chest X-ray, 2 views | 80 | $16 | $61 |
| Irrigation of implanted venous access drug delivery device | 78 | $16 | $114 |
| Hospital follow-up visit, high complexity | 77 | $86 | $357 |
| Infusion, normal saline solution , 1000 cc | 77 | $2 | $19 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 68 | $124 | $500 |
| Unclassified drugs | 62 | $1 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 60 | $15 | $100 |
| Administration of additional new drug or substance into vein using push technique | 59 | $42 | $289 |
| Reticulated (young) platelet measurement | 54 | $35 | $143 |
| New patient office visit, complex (60-74 min) | 53 | $156 | $709 |
| Infusion into a vein for hydration, each additional hour | 47 | $9 | $75 |
| Ferritin level test (iron stores) | 42 | $13 | $60 |
| Iron level test | 42 | $6 | $27 |
| Iron binding capacity test | 42 | $9 | $35 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 39 | $90 | $657 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $15 | $94 |
| Office visit, established patient, complex (40-54 min) | 30 | $130 | $496 |
| Drawing of blood for a medical problem | 29 | $55 | $264 |
| Infusion into a vein for hydration, 31-60 minutes | 27 | $25 | $256 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 26 | $1,109 | $4,802 |
| Application of on-body injector for under skin injection | 26 | $14 | $96 |
| Red blood count automated, with additional calculations | 23 | $5 | $26 |
| CT scan of chest, without contrast | 17 | $44 | $686 |
| Ct scan of abdomen and pelvis without contrast | 17 | $58 | $560 |
| Nuclear medicine study whole body with ct scan | 13 | $1,109 | $4,929 |
| Ct scan of soft tissue of neck with contrast | 12 | $71 | $658 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
47.3% high complexity
47.1% medium
5.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$18,117
Total received (2018-2024)
Avg $2,588/year across 7 years
Top 31% in TX for medical oncology
39
Companies
92
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,903 (54.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,645 (25.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,569 (19.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,756
2023$1,295
2022$2,602
2021$1,362
2020$1,383
2019$858
2018$5,862
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$3,761
TESARO, Inc.
$3,525
CTI BioPharma Corp.
$1,833
BeiGene USA, Inc.
$1,365
AbbVie Inc.
$1,350
F. Hoffmann-La Roche AG
$1,220
E.R. Squibb & Sons, L.L.C.
$512
GENZYME CORPORATION
$447
Janssen Scientific Affairs, LLC
$343
GlaxoSmithKline, LLC.
$323
Pharmacyclics LLC, An AbbVie Company
$276
Amgen Inc.
$257
Lilly USA, LLC
$224
Seagen Inc.
$197
Merck Sharp & Dohme Corporation
$184
Merck Sharp & Dohme LLC
$183
PFIZER INC.
$164
ADC Therapeutics America, Inc.
$145
Clovis Oncology, Inc.
$140
AstraZeneca Pharmaceuticals LP
$132
Novartis Pharmaceuticals Corporation
$131
Mirati Therapeutics, Inc.
$111
Janssen Biotech, Inc.
$109
Kite Pharma, Inc.
$105
Daiichi Sankyo Inc.
$105
Foundation Medicine, Inc.
$100
SANOFI-AVENTIS U.S. LLC
$100
Taiho Oncology, Inc.
$96
Genmab U.S., Inc.
$95
AbbVie, Inc.
$86
Dendreon Pharmaceuticals LLC
$79
Janssen Products, LP
$77
Genentech USA, Inc.
$76
Exelixis Inc.
$75
Astellas Pharma US Inc
$64
Ipsen Biopharmaceuticals, Inc
$38
Seattle Genetics, Inc.
$35
Eisai Inc.
$33
Karyopharm Therapeutics Inc.
$21
Top 3 companies account for 50.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AUGTYRO · BOSULIF · BRUKINSA · Cabometyx · DARZALEX · ELITEK · EMPLICITI · ENJAYMO · Enhertu · Epkinly · Erleada · IMBRUVICA · Imbruvica · JADENU · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Nplate · ONIVYDE · OPDIVO · PROVENGE · Padcev · Perjeta · Pomalyst · REBLOZYL · Rubraca · SARCLISA · SUTENT · TAGRISSO · TEVIMBRA · TIVDAK · Trodelvy · Venclexta · Vonjo · XPOVIO · XTANDI · Yescarta · ZEJULA · ZYTIGA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (55%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $9 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
20.0
County median income
$63,472
Nearest hospital
HENDRICK MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Melnyk is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and consulting-driven industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Melnyk experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Melnyk performed 89,250 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Melnyk receive payments from pharmaceutical companies?
Yes. Dr. Melnyk received a total of $18,117 from 39 companies across 92 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Melnyk's costs compare to other medical oncologys in Abilene?
Dr. Melnyk's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Melnyk) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Abilene
Browse medical oncologys in Abilene ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc..
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc..
By company
CTI BioPharma Corp. Payments to Doctors
See all physicians who received payments from CTI BioPharma Corp..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology